匹伐他汀钙联合依折麦布治疗高龄冠心病合并2型糖尿病患者的疗效及安全性  

Efficacy and safety of pitavastatin combined with ezetimibe in treatment of coronary heart disease with type 2 diabetes mellitus in elderly patients

作　　者：胡广卉[1] 武云涛[2] 赵保钢[3] 姚璐[2] 陈艳梅[2] 刘立新[2] 夏常泉[2] 张薇[2] 

机构地区：[1]北京大兴区人民医院药剂科,北京102600 [2]中国人民解放军陆军总医院干四科,北京100700 [3]北京大兴区人民医院脑外科,北京102600

出　　处：《中国循证心血管医学杂志》2016年第12期1466-1469,共4页Chinese Journal of Evidence-Based Cardiovascular Medicine

摘　　要：目的观察匹伐他汀钙联合依折麦布治疗高龄冠心病合并2型糖尿病患者的疗效及安全性。方法入选2015年1月-2016年1月于陆军总医院住院,年龄大于80岁的老年冠心病合并2型糖尿病患者115例。其中60例低密度脂蛋白胆固醇（LDL-C）不达标（LDL-C≥1.8 mmol/L）患者（观察组）每晚睡前口服匹伐他汀钙2 mg＋依折麦布10 mg,55例LDL-C达标（LDL-C〈1.8 mmol/L）患者（对照组）,继续每晚口服匹伐他汀钙片2 mg,观察疗程共6月,分别于用药前、用药后4周、8周、6月检测总胆固醇（TC）、三酰甘油（TG）、高密度脂蛋白胆固醇（HDL-C）、LDL-C、肌酸磷酸激酶（CK）水平变化,以及肝、肾功能情况。结果对照组治疗后4周、8周、6月TC、LDL-C、HDL-C与治疗前比较,差异无统计学意义（P〉0.05）;观察组治疗后4周、8周、6月TC、LDL-C与治疗前比较明显减低（P〈0.05）,两组HDL-C治疗后4、8周、6月与治疗前比较,差异无统计学意义（P〉0.05）。治疗后肝、肾功能及CPK无明显变化。结论高龄男性老年冠心病合并2型糖尿病患者口服匹伐他汀钙联合依折麦布疗效及安全性均较好。Objective To observe the efficacy and safety of Pitavastatin calcium combined with Ezetimibe in the treatment of coronary heart disease with type 2 diabetes mellitus in elderly patients. Methods 115 elderly patients with coronary heart disease and type 2 diabetes mellitus hospitalized in PLA Army General Hospital from January 2015 to January 2016 were enrolled in the study. 60 patients as observation group [low-density lipoprotein cholesterol（LDL-C）≥1.8 mmol/L] received oral Pitavastatin calcium 2 mg ＋ ezetimibe 10 mg every night before going to bed; and 55 patients as control group [low-density lipoprotein cholesterol（LDL-C） 1.8 mmol/L] received oral Pitavastatin calcium 2 mg every night before going to bed. The levels of total cholesterol（TC）, triglyceride（TG）, high density lipoprotein（HDL-C）, low density lipoprotein（LDL-C）, creatine kinase（CPK） and the liver and kidney function were measured before treatment, 4 weeks after treatment, 8 weeks after treatment and 6 months after treatment. Results There was no significant difference in TC, LDL-C and HDL-C before and after treatment（P〈0.05）. The levels of TC and LDL-C in treatment group were significantly lower than those before treatment（P〈0.05）. There was no significant difference in HDL-C between the two groups before and after treatment（P〈0.05）. After treatment, the liver and kidney function and CPK levels were not significantly changed. Conclusions Efficacy and safety of Pitavastatin calcium combined with Ezetimibe in elderly men with coronary heart disease and type 2 diabetes mellitus were good.

关 键 词：冠心病 2型糖尿病 匹伐他汀钙 依折麦布 老年 

分 类 号：R541.4[医药卫生—心血管疾病]